Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03086616 · ClinicalTrials.gov registry record · Phase 1

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target

NCT03086616 is a Phase 1 study that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03086616, a Phase 1 study, has completed, sponsored by Sabine Mueller, MD, PhD.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target

Study Summary

This is a Phase I and Early Efficacy Study of Convection Enhanced Delivery (CED) of irinotecan liposome injection (nal-IRI) Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma who have completed focal radiotherapy

Interventions

  • DRUG Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2017-10-31
Est. Completion 2021-10-04
Phase Phase 1

Sponsor

Sabine Mueller, MD, PhD

12 total trials

What the Registry Record Tells You About NCT03086616

The ClinicalTrials.gov registry entry for NCT03086616 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI) is the first listed.

NCT03086616 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03086616 about?

NCT03086616 is a clinical study titled "CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)". This is a Phase I and Early Efficacy Study of Convection Enhanced Delivery (CED) of irinotecan liposome injection (nal-IRI) Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma who have completed focal radiotherapy

What is the current status of trial NCT03086616?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-10-31. Estimated completion is 2021-10-04.

What interventions are being tested in trial NCT03086616?

The interventions under investigation include: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI) (DRUG).

Who is sponsoring clinical trial NCT03086616?

This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.